Kohei shitara (@KoheiShitara) / X

Kohei SHITARA, Chief, Department of Gastrointestinal Oncolology

Kohei shitara (@KoheiShitara) / X

Kohei shitara (@KoheiShitara) / X

Kohei SHITARA, Chief, Department of Gastrointestinal Oncolology

Kohei Shitara, Videos & Research

Alexandre Jácome (@AJacomeMD) / X

ASCO #GI22: Gastric and esophageal cancers, HER2-targeted therapy, immunotherapy, ADCs

Kohei Shitara, Videos & Research

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Kohei shitara (@KoheiShitara) / X

Raghav Sundar (@sundar__raghav) / X

Daniel Acosta Eyzaguirre (@DanielAcostaEy1) / X

Kohei Shitara, Videos & Research

Kohei shitara (@KoheiShitara) / X

Kohei shitara (@KoheiShitara) / X